Natick, Massachusetts-based Benu BioPharma established Benu BioVentures, a biopharmaceutical investment initiative to fund and develop preclinical stage pharmaceutical investments to the human proof-of-concept stage.
Led by Dennis Goldberg, Ph.D., FAHA and Fred Meyer, Ph.D., CFA, both biopharmaceutical serial entrepreneurs, Benu BioVentures will focus on product candidates with strong animal data and a clear regulatory path that address unmet medical needs.
It utilizes a virtual company model to move validated candidate drugs into the clinic and establish human safety and efficacy.
FinSMEs
16/09/2013